Parkinson’s Disease Treatment Market Size, Share | Report 2022-2030
The global Parkinson’s disease treatment market size was estimated at around USD 4.3 billion in 2021 and it is projected to hit around USD 12.1 billion by 2030, growing at a CAGR of 12.18% from 2022 to 2030.
Report Highlights
In August 2021, the Parkinson’s Foundation announced an investment of USD 43 million as a research grant to 29 research projects having the goal of developing novel treatments and therapies for PD. In addition, in May 2021, the Parkinson’s Foundation announced an investment of USD 10 million for research, care, and educational programs related to Parkinson’s Disease (PD). This investment may aid in providing awareness and genetic testing free of cost to people suffering from PD.
Such investment initiatives are expected to boost industry growth. In the last ten years, there have been significant R&D activities in the PD therapy sector, leading to the development of innovative drug-delivery methods. Due to fewer side effects, these cutting-edge drug delivery systems outperform the existing ones. In addition, the rate of prescription for these techniques has increased due to a rise in patient compliance, which is fueling the expansion of the industry. Moreover, key pharmaceutical companies are undertaking initiatives, such as collaborations and partnerships, for the development, manufacturing & commercialization of products to meet the rising demand for disease treatment in the international market.
For instance, in November 2021, STADA Arzneimittel and Bioglan formed a partnership to expand the production capacity of the medicine Lecigon (levodopa/carbidopa/entacapone) used to treat patients with PD. Thus, increasing demand for medicines that are used to treat patients with PD is anticipated to drive industry growth. However, the limited availability of neurologists leads to issues, such as longer waiting times for patients and difficulty in hiring new neurosurgeons in hospitals. In addition, some of the currently practicing neurologists avoid accepting new Medicaid patients, which creates difficulty for patients who want to switch to another doctor. According to the American Academy of Neurology (AAN) report, around 19% shortage of neurologists is projected by 2025.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 4.3 billion |
| Revenue Forecast by 2030 | USD 12.1 billion |
| Growth rate from 2022 to 2030 | CAGR of 12.18% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Drug class, distribution channel, region |
| Companies Covered |
Cerevel Therapeutics; Novartis AG; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; GlaxoSmithKline plc. (GSK); AbbVie, Inc.; H. Lundbeck A/S; Amneal Pharmaceuticals LLC; Supernus Pharmaceuticals, Inc. |
Drug Class Insights
The Carbidopa-levodopa drug class segment dominated the industry with a revenue share of more than 25.02% in 2021. This growth was attributed to the high prescription rate of these drugs. According to the U.S. Drug Use Statistics, the estimated number of Carbidopa-Levodopa prescriptions was found to be 527,530 for 183,690 Parkinson’s patients in 2020. Carbidopa and Levodopa are a combination of medicines indicated to treat symptoms of PD. It is the most potent and highly used medication for PD as a second line of treatment. It is primarily available in the oral route of administration, such as in the form of immediate-release tablets, controlled-release tablets, enteral suspension, and extended-release capsules.
Furthermore, the presence of pipeline candidates such as LY03003, coupled with a rise in the demand for dopamine agonists, are factors expected to positively contribute to segment growth. According to the American PD Association (APDA), currently, there are four FDA-approved Dopamine Agonists, which include Requip (ropinirole), Mirapex (pramipexole), Apokyn (apomorphine), and Neupro (rotigotine), available in the U.S. to treat patients suffering from PD. Ropinirole and Pramipexol are available in both long-acting and regular formulations. Apomorphine is delivered by intravenous injection and is considered rescue medication within 10 minutes. Therefore, the approval of novel medicines for the treatment of the disease will also drive segment growth.
Distribution Channel Insights
The retail pharmacy segment dominated the global industry in 2021 and accounted for the largest share of 59.2% of the overall revenue. The segment is anticipated to expand further at the fastest growth rate during the forecast period. According to Parkinson’s news today, PD affects around 41 individuals per 100,000 in their 40s, to more than 1,900 people per 100,000 in their 80s and 90s. It is the second-most common neurodegenerative disorder after Alzheimer’s disease. Currently, PD is not completely curable and it takes lifelong support of medications. The majority of this medication consumption is associated with retail pharmacies. All these factors are expected to propel the segment growth during the projection period.
Furthermore, the ease of availability of PD drugs including generic carbidopa-levodopa, pramipexole dihydrochloride, selegiline hydrochloride, and others in retail pharmacy chains, such as Walgreens and Walmart Stores, boosts the segment growth. The online pharmacy segment is expected to witness a significant growth rate during the forecast period. The trend of online shopping is growing due to the comfort, flexibility, and convenience offered by these platforms. This, in turn, is generating high revenues, thereby driving the growth of the online segment. Moreover, online shopping offers various discounts, benefiting customers. This factor is expected to boost the demand for online pharmacies during the forecast period.
Regional Insights
North America dominated the global industry with a maximum revenue share of 37.95% in 2021. This dominance can be attributed to the presence of leading players in the region, such as AbbVie Inc., Merck & Co. Inc., Amneal Pharmaceuticals LLC., and Sunovion Pharmaceuticals Inc. These players support growth by introducing new PD symptom management products. For instance, in May 2020, the U.S. FDA approved Kynmobi developed by Sunovion Pharmaceuticals Inc., to treat off-episodes in patients with PD. Furthermore, extensive research in the field of PD in the region is anticipated to positively contribute to the market growth.
For instance, in Canada, in January 2022, BlueRock Therapeutics administered the first dose of DA01 (dopaminergic neurons) in patients with advanced PD. Successful completion of the trial and subsequent approval of the product is anticipated to drive the region’s growth during the forecast period. Asia Pacific is estimated to register the fastest growth rate during the assessment period. This is due to the increased product penetration, untapped potential, and growing prevalence of PD in developing countries. For instance, in July 2022, UCB S.A. received an Import Drug License (IDL) from the China Food and Drug Administration (CFDA) for the supply and delivery of Neupro in China. Neupro is recommended as a monotherapy in combination with levodopa to treat patients with early-stage idiopathic PD.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Parkinson’s Disease Treatment Market
5.1. COVID-19 Landscape: Parkinson’s Disease Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Parkinson’s Disease Treatment Market, By Drug Class
8.1. Parkinson’s Disease Treatment Market, by Drug Class, 2022-2030
8.1.1. Carbidopa-levodopa
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Dopamine Agonists
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. MAO-B Inhibitors
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. COMT inhibitors
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Anticholinergics
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Parkinson’s Disease Treatment Market, By Distribution Channel
9.1. Parkinson’s Disease Treatment Market, by Distribution Channel, 2022-2030
9.1.1. Hospital Pharmacy
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Retail Pharmacy
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Online Pharmacy
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Parkinson’s Disease Treatment Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.1.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.1.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.5.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 11. Company Profiles
11.1. Cerevel Therapeutics
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Novartis AG
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Teva Pharmaceutical Industries Ltd.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Merck & Co., Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. GlaxoSmithKline plc. (GSK)
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. AbbVie, Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. H. Lundbeck A/S
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Amneal Pharmaceuticals LLC
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Supernus Pharmaceuticals, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers